Javascript must be enabled to continue!
Modeling the immunological pre-adaptation of HIV-1
View through CrossRef
Abstract
It is becoming increasingly evident that the evolution of HIV-1 is to a large extent determined by the immunological background of the host. On the population-level this results in associations between specific human leukocyte antigen (HLA) alleles and polymorphic loci of the virus. Furthermore, some HLA alleles that were previously associated with slow progression to AIDS have been shown to lose their protective effect, because HLA-specific immunological escape variants have spread through the population. This phenomenon is known as immunological pre-adaptation. Apart from adapting to human immune responses, the set-point virus load (SPVL) of HIV-1 is thought to have evolved to values that optimize the population-level fitness of the virus. This suggestion is supported by considerable heritability of the SPVL. Previous modeling studies show that whether or not SPVL optimization is expected to occur depends sensitively on the underlying assumptions with respect to the extent of within-versus between-host selection. Here we use a detailed and semi-realistic multi-level HIV-1 model in which immunological pre-adaptation and SPVL evolution can emerge from the underlying interactions of the virus with the immune system of the host. This enables us to study the effect of immunological escape on disease progression, and how disease progression may be molded by SPVL evolution. We find that the time to AIDS could decrease significantly (0.5-1.0 years) in a HLA-dependent manner by immunological pre-adaptation over the long-term course of the epidemic (> 100 years). We find that SPVL is not expected to evolve to optimize the population-level fitness of HIV-1, even though high heritability of the SPVL emerges from continual selection of immune-escape mutations.
Title: Modeling the immunological pre-adaptation of HIV-1
Description:
Abstract
It is becoming increasingly evident that the evolution of HIV-1 is to a large extent determined by the immunological background of the host.
On the population-level this results in associations between specific human leukocyte antigen (HLA) alleles and polymorphic loci of the virus.
Furthermore, some HLA alleles that were previously associated with slow progression to AIDS have been shown to lose their protective effect, because HLA-specific immunological escape variants have spread through the population.
This phenomenon is known as immunological pre-adaptation.
Apart from adapting to human immune responses, the set-point virus load (SPVL) of HIV-1 is thought to have evolved to values that optimize the population-level fitness of the virus.
This suggestion is supported by considerable heritability of the SPVL.
Previous modeling studies show that whether or not SPVL optimization is expected to occur depends sensitively on the underlying assumptions with respect to the extent of within-versus between-host selection.
Here we use a detailed and semi-realistic multi-level HIV-1 model in which immunological pre-adaptation and SPVL evolution can emerge from the underlying interactions of the virus with the immune system of the host.
This enables us to study the effect of immunological escape on disease progression, and how disease progression may be molded by SPVL evolution.
We find that the time to AIDS could decrease significantly (0.
5-1.
0 years) in a HLA-dependent manner by immunological pre-adaptation over the long-term course of the epidemic (> 100 years).
We find that SPVL is not expected to evolve to optimize the population-level fitness of HIV-1, even though high heritability of the SPVL emerges from continual selection of immune-escape mutations.
Related Results
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Background: HIV/AIDS remains a global health problem in Indonesia, with major barriers being misunderstandings, social stigma, and ineffective educational approaches. The level of ...
Spatial immune dynamics in mucosal HIV infection
Spatial immune dynamics in mucosal HIV infection
<p dir="ltr">Sexual transmission is the most common mode of HIV infection, making the female genital and rectal tracts critical mucosal sites for preventing HIV transmission....
Spatial immune dynamics in mucosal HIV infection
Spatial immune dynamics in mucosal HIV infection
<p dir="ltr">Sexual transmission is the most common mode of HIV infection, making the female genital and rectal tracts critical mucosal sites for preventing HIV transmission....
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract
BACKGROUND: Paraproteinemias occur in 1 to 3% of people over the age of 50 and progress to hematological malignancies (HM) at the rate of about 1% per year....

